Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Chen, Yun ^a   Guo, Yao ^b   Han, Jiayu ^a   Ho, Wanting Tina ^a   Li, Shibo ^a   Fu, Xueqi ^b   Zhao, Zhizhuang Joe ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Activity assay; Acute myeloid leukemia; FLT3; Inhibitor screening; Tyrosine kinase

Indexed keywords

CD135 ANTIGEN; DASATINIB; ERLOTINIB; GEFITINIB; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; IMATINIB; LESTAURTINIB; NILOTINIB; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; SORAFENIB; SUNITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOPHOSPHORYLATION; BACULOVIRUS; BONE MARROW CELL; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

BONE MARROW; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 84865229701     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-39     Document Type: Article

References (15)

1. The roles of FLT3 in hematopoiesis and leukemia. DG Gilliland, JD Griffin, Blood 2002 100 1532 1542 10.1182/blood-2002-02-0492 12176867 (Pubitemid 34925124)
2. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. K Masson, L Rönnstrand, Cell Signal 2009 21 1717 1726 10.1016/j.cellsig.2009.06.002 19540337
3. The role of FLT3 in hematopoietic malignancies. DL Stirewalt, JP Radich, Nat Rev Cancer 2003 3 650 665 10.1038/nrc1169 12951584
4. Current findings for recurring mutations in acute myeloid leukemia. S Takahashi, J Hematol Oncol 2011 4 36 10.1186/1756-8722-4-36 21917154
5. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. S Takahashi, J Hematol Oncol 2011 4 13 10.1186/1756-8722-4-13 21453545
6. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, M Habdank, D Späth, M Morgan, A Benner, B Schlegelberger, G Heil, A Ganser, H Döhner, N Engl J Med 2008 358 1909 1918 10.1056/NEJMoa074306 18450602 (Pubitemid 351620111)
7. Diagnosis and prognosis in acute myeloid leukemia-the art of distinction. B Lowenberg, N Engl J Med 2008 358 1960 1962 10.1056/NEJMe0802379 18450608 (Pubitemid 351620119)
8. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. TK Gregory, D Wald, Y Chen, JM Vermaat, Y Xiong, W Tse, J Hematol Oncol 2009 2 23 10.1186/1756-8722-2-23 19490647
9. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. X Zhu, Y Ma, D Liu, J Hematol Oncol 2010 3 17 10.1186/1756-8722-3-17 20416083
10. FLT3 inhibitors: a story of the old and the new. A Fathi, M Levis, Curr Opin Hematol 2011 18 71 76 10.1097/MOH.0b013e3283439a03 21245757
11. Bench to Bedside Targeting of FLT3 in Acute Leukemia. KW Pratz, MJ Levis, Curr Drug Targets 2010 11 781 789 10.2174/138945010791320782 20370649
12. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. BD Smith, M Levis, M Beran, F Giles, H Kantarjian, K Berg, KM Murphy, T Dauses, J Allebach, D Small, Blood 2004 103 3669 3676 10.1182/blood-2003-11-3775 14726387 (Pubitemid 38596280)
13. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. AT Fathi, BA Chabner, Oncologist 2011 16 1162 1174 10.1634/theoncologist.2011-0084 21765192
14. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. Z Li, M Xu, S Xing, WT Ho, T Ishii, Q Li, X Fu, ZJ Zhao, J Biol Chem 2007 282 3428 3432 17178722 (Pubitemid 47084420)
15. Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Z Li, S Xing, S Wang, WT Ho, ZJ Zhao, Exp Hematol 2007 35 1624 1632 10.1016/j.exphem.2007.07.003 17764811 (Pubitemid 47633769)